FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980094802> ?p ?o ?g. }

• W2980094802 abstract "Abstract Patients with acute myeloid leukemia (AML) who receive intensive chemotherapy regimens containing high-dose cytarabine are at high risk for bacterial sepsis due to prolonged neutropenia and severe mucositis. To determine if the use of prophylactic antibiotics during periods of neutropenia reduced bacterial infections and viridans streptococcal infections (VSI) in particular, we reviewed the charts of 66 AML patients who were treated on our front line protocol (AML02) from October 2002 to June 2006. During this time, several consecutive prophylactic antibiotic strategies were implemented for use after intensive myelosuppressive therapy. All patients also received prophylactic antifungal therapy. Overall, patients who received any prophylactic antibiotic regimen had an 86% (95% CI: 66–95%) reduction in VSI (P<0.001) and a 76% (95% CI: 62–85%) reduction in all bacterial infections (P<0.001), compared to those who did not receive prophylactic antibiotics. Oral cephalosporins were used initially and were found to be ineffective at preventing overall bacterial infections (P=0.97) or VSI (P=0.70). Intravenous cefepime was then implemented and completely prevented VSI. Furthermore, there was an 84% (95% CI: 52–94%) reduction in all bacterial infections (P<0.001). However, because we observed the emergence of life-threatening resistant gram-negative infections in two patients receiving cefepime, we instituted the prophylactic use of intravenous vancomycin with oral ciprofloxacin. The use of a vancomycin regimen resulted in an 84% (95% CI: 66–92%) decrease in total bacterial infections (P<0.001) and a 97% (95 CI: 78–100%) decrease in VSI (P<0.001). Importantly, fungal infection rates were similar in patients who received prophylactic antibiotics compared to those who did not (0.9 vs. 1.0 infection per 1000 patient days). Patients who received prophylactic antibiotics had shorter lengths of hospital stay (LOS), with a median (range) of 7 days (0–39) vs. 15 days (0–56) for each course of chemotherapy. After adjusting for course of therapy, this represented a 38% (95% CI: 24–50%) reduction in total LOS. Patients who received a vancomycin regimen had a 46% (95% CI: 28–59%) reduction in LOS (P<0.001) and those who received intravenous cefepime a 31% (95% CI: 9–47%) reduction (P=0.008) compared to patients who did not receive prophylactic antibiotics. Overall, there was only one death from septicemia; this occurred in a patient who was not receiving prophylactic antibiotics. In conclusion, this study suggests that supportive care with antibiotic prophylaxis during periods of neutropenia may dramatically decrease the incidence of septicemia and length of hospitalization. While intravenous cefepime was found to be effective prophylaxis for VSI and other bacterial infections, we have avoided its use because of concern for emerging resistance to our front-line empiric therapy for fever and neutropenia. Thus, intravenous vancomycin with oral ciprofloxacin is our prophylactic antibiotic regimen of choice. We did not administer ciprofloxacin alone, as this has previously been shown to increase the risk of infections with gram positive organisms. Further research is needed to determine the most effective antibiotic regimen for prevention of bacterial infection in pediatric patients with AML." @default.
• W2980094802 created "2019-10-18" @default.
• W2980094802 creator A5001311437 @default.
• W2980094802 creator A5014737395 @default.
• W2980094802 creator A5018363328 @default.
• W2980094802 creator A5019515936 @default.
• W2980094802 creator A5043719444 @default.
• W2980094802 creator A5064611054 @default.
• W2980094802 creator A5066486945 @default.
• W2980094802 creator A5066681200 @default.
• W2980094802 creator A5086250633 @default.
• W2980094802 date "2006-11-16" @default.
• W2980094802 modified "2023-10-17" @default.
• W2980094802 title "Prophylactic Antibiotics Reduce Morbidity from Septicemia during Intensive Treatment for Pediatric Acute Myelogenous Leukemia." @default.
• W2980094802 doi "https://doi.org/10.1182/blood.v108.11.1919.1919" @default.
• W2980094802 hasPublicationYear "2006" @default.
• W2980094802 type Work @default.
• W2980094802 sameAs 2980094802 @default.
• W2980094802 citedByCount "0" @default.
• W2980094802 crossrefType "journal-article" @default.
• W2980094802 hasAuthorship W2980094802A5001311437 @default.
• W2980094802 hasAuthorship W2980094802A5014737395 @default.
• W2980094802 hasAuthorship W2980094802A5018363328 @default.
• W2980094802 hasAuthorship W2980094802A5019515936 @default.
• W2980094802 hasAuthorship W2980094802A5043719444 @default.
• W2980094802 hasAuthorship W2980094802A5064611054 @default.
• W2980094802 hasAuthorship W2980094802A5066486945 @default.
• W2980094802 hasAuthorship W2980094802A5066681200 @default.
• W2980094802 hasAuthorship W2980094802A5086250633 @default.
• W2980094802 hasConcept C126322002 @default.
• W2980094802 hasConcept C141071460 @default.
• W2980094802 hasConcept C177713679 @default.
• W2980094802 hasConcept C2776694085 @default.
• W2980094802 hasConcept C2777063308 @default.
• W2980094802 hasConcept C2778041864 @default.
• W2980094802 hasConcept C2778384902 @default.
• W2980094802 hasConcept C2778496288 @default.
• W2980094802 hasConcept C2778850193 @default.
• W2980094802 hasConcept C501593827 @default.
• W2980094802 hasConcept C71924100 @default.
• W2980094802 hasConcept C86803240 @default.
• W2980094802 hasConcept C89423630 @default.
• W2980094802 hasConceptScore W2980094802C126322002 @default.
• W2980094802 hasConceptScore W2980094802C141071460 @default.
• W2980094802 hasConceptScore W2980094802C177713679 @default.
• W2980094802 hasConceptScore W2980094802C2776694085 @default.
• W2980094802 hasConceptScore W2980094802C2777063308 @default.
• W2980094802 hasConceptScore W2980094802C2778041864 @default.
• W2980094802 hasConceptScore W2980094802C2778384902 @default.
• W2980094802 hasConceptScore W2980094802C2778496288 @default.
• W2980094802 hasConceptScore W2980094802C2778850193 @default.
• W2980094802 hasConceptScore W2980094802C501593827 @default.
• W2980094802 hasConceptScore W2980094802C71924100 @default.
• W2980094802 hasConceptScore W2980094802C86803240 @default.
• W2980094802 hasConceptScore W2980094802C89423630 @default.
• W2980094802 hasLocation W29800948021 @default.
• W2980094802 hasOpenAccess W2980094802 @default.
• W2980094802 hasPrimaryLocation W29800948021 @default.
• W2980094802 hasRelatedWork W1525555991 @default.
• W2980094802 hasRelatedWork W1990677620 @default.
• W2980094802 hasRelatedWork W1997211134 @default.
• W2980094802 hasRelatedWork W2019219302 @default.
• W2980094802 hasRelatedWork W2078472716 @default.
• W2980094802 hasRelatedWork W2129285781 @default.
• W2980094802 hasRelatedWork W2268141475 @default.
• W2980094802 hasRelatedWork W2393336126 @default.
• W2980094802 hasRelatedWork W2902654642 @default.
• W2980094802 hasRelatedWork W70851270 @default.
• W2980094802 isParatext "false" @default.
• W2980094802 isRetracted "false" @default.
• W2980094802 magId "2980094802" @default.
• W2980094802 workType "article" @default.